Facility addition expected to increase production capacity of TNAs.
Agilent Technologies Inc., a life sciences organization, has officially broken ground on an $725 million expansion to its manufacturing facility in Frederick, Colo. The addition—the company notes—is expected to double its therapeutic nucleic acid (TNA) production capacity.
The project aims to increase US manufacturing for active pharmaceutical ingredients (APIs) that are involved in the treatment of various diseases, including cancer and cardiovascular disease, along with rare and infectious diseases. This addition will specifically focus on providing oligonucleotide API material, which can be used as adjuvants in vaccine development. Current good manufacturing practices (cGMPs) will be followed all the way through commercialization.
"… We are very excited about this next phase of investment in this rapidly growing area of biotechnology,” says Mike McMullen, CEO of Agilent. “We’re proud to be helping to drive this growth by creating innovative therapeutics that improve the quality of life.”